The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) is a huge mover today! The stock increased 1.01% or $0.08 during the last trading session, hitting $7.99. About 291,547 shares traded hands or 250.08% up from the average. Dimension Therapeutics Inc (NASDAQ:DMTX) has risen 12.04% since February 26, 2016 and is uptrending. It has outperformed by 1.61% the S&P500.
The move comes after 8 months positive chart setup for the $183.30M company. It was reported on Oct, 1 by Barchart.com. We have $12.78 PT which if reached, will make NASDAQ:DMTX worth $109.98 million more.
Analysts await Dimension Therapeutics Inc (DMTX) to report earnings on December, 2. They expect $-0.50 EPS, up 81.68% or $2.23 from last year’s $-2.73 per share. After $-0.49 actual EPS reported by Dimension Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.04% negative EPS growth.
Dimension Therapeutics Inc (NASDAQ:DMTX) Ratings Coverage
Out of 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dimension Therapeutics has been the topic of 9 analyst reports since November 6, 2015 according to StockzIntelligence Inc. Citigroup initiated it with “Buy” rating and $18 target price in Monday, November 16 report. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The rating was initiated by Canaccord Genuity on Monday, November 16 with “Buy”. Goldman Sachs initiated the stock with “Buy” rating in Friday, December 4 report. The firm earned “Buy” rating on Friday, June 3 by Cantor Fitzgerald. The rating was initiated by Goldman Sachs with “Buy” on Monday, November 16. Roth Capital initiated the shares of DMTX in a report on Friday, November 6 with “Buy” rating. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) earned “Buy” rating by Cantor Fitzgerald on Thursday, February 18.
According to Zacks Investment Research, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.”
More notable recent Dimension Therapeutics Inc (NASDAQ:DMTX) news were published by: Wsj.com which released: “In Latest Setback for Biotech IPOs, Dimension Therapeutics Shares Fall in Debut” on October 22, 2015, also Businesswire.com with their article: “Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing” published on April 21, 2015, Globenewswire.com published: “Dimension Therapeutics to Present at the Cantor Fitzgerald 2nd Annual …” on June 29, 2016. More interesting news about Dimension Therapeutics Inc (NASDAQ:DMTX) were released by: Bizjournals.com and their article: “â€‹After fast buildup, Dimension Therapeutics aims at execution in 2016” published on February 11, 2016 as well as Globenewswire.com‘s news article titled: “Dimension Therapeutics Announces Initiation of Phase 1/2 Study for DTX101 for …” with publication date: January 07, 2016.
DMTX Company Profile
Dimension Therapeutics, Inc., incorporated on June 20, 2013, is a gene therapy company. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Firm has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV) vector delivery technology. The Firm uses mammalian cells in its manufacturing approach for its AAV product candidates. The Company’s AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.